Related Experiment Video
Updated: Jan 30, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
Irene Russo1, Ludovica Zorzetto1, Vanna Chiarion Sileni2
1Unit of Dermatology, University of Padua, Via Gallucci 4, 35128 Padova, Italy.
Abstract:
Melanoma is one of the most fatal cancers, and its incidence is increasing worldwide. Thanks to the better understanding of the molecular mechanisms involved in the pathogenesis of melanoma, recently new targeted agents have been developed. In this article, we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common cutaneous side effects observed during treatment with targeted and immunological therapies approved for advanced melanoma. We include discussion of BRAF/MEK inhibitors and immune-checkpoint inhibitors, notably CTLA-4 and PD-1 inhibitors.
Insights
Targeted and immune therapies for advanced melanoma can cause skin side effects. This review covers their presentation, mechanisms, and management, focusing on BRAF/MEK and immune-checkpoint inhibitors.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Melanoma incidence is rising globally, necessitating advanced treatments.
- Recent advances in understanding melanoma pathogenesis have led to new targeted and immunotherapies.
- Cutaneous side effects are common with these advanced melanoma treatments.
Purpose of the Study:
- To review the clinical presentation, mechanisms, and management of side effects from advanced melanoma therapies.
- To discuss side effects associated with BRAF/MEK inhibitors.
- To cover side effects related to immune-checkpoint inhibitors, including CTLA-4 and PD-1 inhibitors.
Main Methods:
- Literature review of clinical presentations.
- Review of pathomechanisms of treatment-related side effects.
- Compilation of management strategies for cutaneous adverse events.
Main Results:
- Targeted therapies (BRAF/MEK inhibitors) and immunotherapies (CTLA-4, PD-1 inhibitors) are associated with specific cutaneous side effects.
- Understanding the mechanisms aids in predicting and managing these adverse events.
- Effective management strategies can mitigate treatment toxicity and improve patient outcomes.
Conclusions:
- Cutaneous side effects are a significant clinical consideration in advanced melanoma treatment.
- Proactive identification and management of these side effects are crucial for patient care.
- Further research into optimizing treatment tolerability is warranted.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Gene Therapy
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Extraction: Advanced Methods
Group Therapy

